Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models
Abstract A significant challenge in the development of long-acting injectable drug formulations, especially for anti-infective agents, is delivering an efficacious dose within a tolerable injection volume. Co-administration of the extracellular matrix-degrading enzyme hyaluronidase can increase maximum tolerable injection volumes but is untested for this benefit with long-acting injectable formulations. One concern is that hyaluronidase could potentially alter the tissue response surrounding an injection depot, a response known to be important for drug release kinetics of long-acting injectable formulations. The objective of this pilot study was to evaluate the impact of co-administration of hyaluronidase on the drug release kinetics, pharmacokinetic profiles, and injection site histopathology of the long-acting injectable paliperidone palmitate for up to four weeks following intramuscular injection in mouse and rat models. In both species, co-administration of hyaluronidase increased paliperidone plasma exposures the first week after injection but did not negate the overall long-acting release nature of the formulation. Hyaluronidase-associated modification of the injection site depot was observed in mice but not in rats. These findings suggest that further investigation of hyaluronidase with long-acting injectable agents is warranted..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 09. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pertinez, Henry [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.03.03.583160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI042843235 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI042843235 | ||
| 003 | DE-627 | ||
| 005 | 20240310091451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.03.03.583160 |2 doi | |
| 035 | |a (DE-627)XBI042843235 | ||
| 035 | |a (biorXiv)10.1101/2024.03.03.583160 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pertinez, Henry |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract A significant challenge in the development of long-acting injectable drug formulations, especially for anti-infective agents, is delivering an efficacious dose within a tolerable injection volume. Co-administration of the extracellular matrix-degrading enzyme hyaluronidase can increase maximum tolerable injection volumes but is untested for this benefit with long-acting injectable formulations. One concern is that hyaluronidase could potentially alter the tissue response surrounding an injection depot, a response known to be important for drug release kinetics of long-acting injectable formulations. The objective of this pilot study was to evaluate the impact of co-administration of hyaluronidase on the drug release kinetics, pharmacokinetic profiles, and injection site histopathology of the long-acting injectable paliperidone palmitate for up to four weeks following intramuscular injection in mouse and rat models. In both species, co-administration of hyaluronidase increased paliperidone plasma exposures the first week after injection but did not negate the overall long-acting release nature of the formulation. Hyaluronidase-associated modification of the injection site depot was observed in mice but not in rats. These findings suggest that further investigation of hyaluronidase with long-acting injectable agents is warranted. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Kaushik, Amit |4 aut | |
| 700 | 1 | |a Curley, Paul |4 aut | |
| 700 | 1 | |a Arshad, Usman |4 aut | |
| 700 | 1 | |a El-Khateeb, Eman |4 aut | |
| 700 | 1 | |a Li, Si-Yang |4 aut | |
| 700 | 1 | |a Tasneen, Rokeya |4 aut | |
| 700 | 1 | |a Sharp, Joanne |4 aut | |
| 700 | 1 | |a Kijak, Edyta |4 aut | |
| 700 | 1 | |a Herriott, Joanne |4 aut | |
| 700 | 1 | |a Neary, Megan |4 aut | |
| 700 | 1 | |a Noë, Michaël |4 aut | |
| 700 | 1 | |a Flexner, Charles |4 aut | |
| 700 | 1 | |a Nuermberger, Eric |4 aut | |
| 700 | 1 | |a Owen, Andrew |4 aut | |
| 700 | 1 | |a Ammerman, Nicole C. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 09. März |
| 773 | 1 | 8 | |g year:2024 |g day:09 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.03.03.583160 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 09 |c 03 | ||